Benjamin Bonavida

List of Publications by Year
in descending order

197	8,098	31976 53	54911 84
papers	citations	h-index	g-index

198	198	198	8110
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs. Cancer Biotherapy and Radiopharmaceuticals, 1997, 12, 177-186.	1.0	350
2	Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention. Journal of Experimental and Clinical Cancer Research, 2014, 33, 62.	8.6	345
3	Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20) Tj ETQq1 1 0.784314 rgBT /Overloc Oncogene, 2005, 24, 2121-2143.	5.9	258
4	Trop2 and its overexpression in cancers: regulation and clinical/ therapeutic implications. Genes and Cancer, 2014, 6, 84-105.	1.9	200
5	Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clinical Cancer Research, 2003, 9, 316-26.	7.0	195
6	Inhibition of the Rafâ€“MEK1/2â€“ERK1/2 Signaling Pathway, Bcl-xL Down-Regulation, and Chemosensitization of Non-Hodgkinâ€™s Lymphoma B Cells by Rituximab. Cancer Research, 2004, 64, 7117-7126.	0.9	188
7	Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-ÎºB and inhibition of Bcl-xL expression. Oncogene, 2004, 23, 4993-5003.	5.9	166
8	Development of Rituximab-Resistant Lymphoma Clones with Altered Cell Signaling and Cross-Resistance to Chemotherapy. Cancer Research, 2007, 67, 1270-1281.	0.9	154
9	Nitric Oxide Inhibits the Transcription Repressor Yin-Yang 1 Binding Activity at the Silencer Region of the Fas Promoter: A Pivotal Role for Nitric Oxide in the Up-Regulation of Fas Gene Expression in Human Tumor Cells. Journal of Immunology, 2001, 167, 75-81.	0.8	148
10	Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Molecular Cancer Therapeutics, 2007, 6, 1387-1399.	4.1	144
11	Novel therapeutic applications of nitric oxide donors in cancer: Roles in chemo- and immunosensitization to apoptosis and inhibition of metastases. Nitric Oxide - Biology and Chemistry, 2008, 19, 152-157.	2.7	142
12	Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Research, 2005, 65, 264-76.	0.9	134
13	Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistance. Oncogene, 2004, 23, 3530-3540.	5.9	131
14	The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-ÂB/Snail/RKIP/PTEN Circuit. Genes and Cancer, 2010, 1, 409-420.	1.9	127
15	Rituximab-Induced Inhibition of YY1 and Bcl-xLExpression in Ramos Non-Hodgkinâ€™s Lymphoma Cell Line via Inhibition of NF-ÎºB Activity: Role of YY1 and Bcl-xLin Fas Resistance and Chemoresistance, Respectively. Journal of Immunology, 2005, 175, 2174-2183.	0.8	126
16	Yin Yang 1 is associated with cancer stem cell transcription factors (SOX2, OCT4, BMI1) and clinical implication. Journal of Experimental and Clinical Cancer Research, 2016, 35, 84.	8.6	126
17	Dual role of NO donors in the reversal of tumor cell resistance and EMT: Downregulation of the NF-ÎºB/Snail/YY1/RKIP circuitry. Nitric Oxide - Biology and Chemistry, 2011, 24, 1-7.	2.7	121
18	The Activated NF-ÎºB-Snail-RKIP Circuitry in Cancer Regulates Both the Metastatic Cascade and Resistance to Apoptosis by Cytotoxic Drugs. Critical Reviews in Immunology, 2009, 29, 241-254.	0.5	116

#	Article	IF	Citations
19	Therapeutic potential of nitric oxide in cancer. Drug Resistance Updates, 2006, 9, 157-173.	14.4	106
20	Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeutics. Redox Biology, 2015, 6, 486-494.	9.0	104
21	Regulation of Tumor Cell Sensitivity to TRAIL-Induced Apoptosis by the Metastatic Suppressor Raf Kinase Inhibitor Protein via Yin Yang 1 Inhibition and Death Receptor 5 Up-Regulation. Journal of Immunology, 2007, 179, 5441-5453.	0.8	101
22	Nitric Oxide Sensitizes Ovarian Tumor Cells to Fas-Induced Apoptosis. Gynecologic Oncology, 1999, 73, 257-264.	1.4	100
23	Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene, 2005, 24, 8114-8127.	5.9	97
24	Mechanisms of nitric oxide-mediated inhibition of EMT in cancer. Cell Cycle, 2010, 9, 4931-4940.	2.6	97
25	Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosation. Biochemical and Biophysical Research Communications, 2005, 336, 692-701.	2.1	96
26	Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosensitization. Cancer Research, 2009, 69, 8376-8385.	0.9	95
27	Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: Role of XIAP in resistance. Prostate, 2002, 53, 286-299.	2.3	92
28	NF-??B in the pathogenesis and treatment of multiple myeloma. Current Opinion in Hematology, 2008, 15, 391-399.	2.5	91
29	Modification of Gene Products Involved in Resistance to Apoptosis in Metastatic Colon Cancer Cells: Roles of Fas, Apaf-1, NFÎºB, IAPs, Smac/DIABLO, and AIF. Journal of Surgical Research, 2007, 142, 184-194.	1.6	83
30	Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1. Nitric Oxide - Biology and Chemistry, 2009, 20, 39-52.	2.7	81
31	YY1 regulates cancer cell immune resistance by modulating PD-L1 expression. Drug Resistance Updates, 2019, 43, 10-28.	14.4	81
32	Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Molecular Cancer Therapeutics, 2004, 3, 71-84.	4.1	81
33	Inhibition of Yin Yang 1-Dependent Repressor Activity of DR5 Transcription and Expression by the Novel Proteasome Inhibitor NPI-0052 Contributes to its TRAIL-Enhanced Apoptosis in Cancer Cells. Journal of Immunology, 2008, 180, 6199-6210.	0.8	78
34	Exosomes derived from cancerous and non-cancerous cells regulate the anti-tumor response in the tumor microenvironment. Genes and Cancer, 2018, 9, 87-100.	1.9	76
35	Blocking signaling through the gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer, 1999, 85, 134-144.	4.1	75
36	The Novel Role of Yin Yang 1 in the Regulation of Epithelial to Mesenchymal Transition in Cancer Via the Dysregulated NF-ÎºB/Snail/YY1/RKIP/PTEN Circuitry. Critical Reviews in Oncogenesis, 2011, 16, 211-226.	0.4	75

#	Article	IF	Citations
37	Nitric oxide-mediated activity in anti-cancer photodynamic therapy. Nitric Oxide - Biology and Chemistry, 2013, 30, 26-35.	2.7	75
38	X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pI (Smac/DIABLO). Molecular Cancer Therapeutics, 2002, 1, 1051-8.	4.1	75
39	Expression of X-Linked Inhibitor of Apoptosis Protein Is a Strong Predictor of Human Prostate Cancer Recurrence. Clinical Cancer Research, 2007, 13, 6056-6063.	7.0	74
40	Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity. , 1997, 79, 1180-1189.		73
41	ENHANCED SENSITIVITY OF BLADDER CANCER CELLS TO TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND MEDIATED APOPTOSIS BY CISPLATIN AND CARBOPLATIN. Journal of Urology, 2001, 165, 263-270.	0.4	72
42	Reversal of Tumor Resistance to Apoptotic Stimuli by Alteration of Membrane Fluidity: Therapeutic Implications. Advances in Cancer Research, 2007, 98, 149-190.	5.0	71
43	Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Molecular Cancer Therapeutics, 2003, 2, 1183-93.	4.1	70
44	Involvement of the TNF-Î± autocrineâ€“paracrine loop, via NF-ÎºB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis. Clinical Immunology, 2006, 120, 297-309.	3.2	69
45	Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. Cancer, 1994, 74, 2546-2554.	4.1	68
46	Interferon-? activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-? secretion by immature human natural killer cells. Journal of Clinical Immunology, 1995, 15, 35-44.	3.8	68
47	Expression of transcription factor Yin Yang 1 in prostate cancer. International Journal of Oncology, 2005, 27, 131-41.	3.3	68
48	Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clinical Cancer Research, 2002, 8, 836-45.	7.0	66
49	Nitric Oxide Disrupts H2O2-dependent Activation of Nuclear Factor ÎºB. Journal of Biological Chemistry, 2001, 276, 8918-8923.	3.4	65
50	Dual roles of nitric oxide in the regulation of tumor cell response and resistance to photodynamic therapy. Redox Biology, 2015, 6, 311-317.	9.0	65
51	Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions. Clinical Cancer Research, 2009, 15, 6582-6594.	7.0	59
52	Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer. Nitric Oxide - Biology and Chemistry, 2013, 29, 17-24.	2.7	57
53	Nitric oxide donors: novel cancer therapeutics (review). International Journal of Oncology, 2008, 33, 909-27.	3.3	57
54	Chemosensitization and Immunosensitization of Resistant Cancer Cells to Apoptosis and Inhibition of Metastasis by the Specific NF-κB Inhibitor DHMEQ. Current Pharmaceutical Design, 2009, 15, 792-808.	1.9	56

#	Article	IF	Citations
55	Actinomycin D and Gemcitabine Synergistically Sensitize Androgen-Independent Prostate Cancer Cells to Apo2L/TRAIL-Mediated Apoptosis. Journal of Immunotherapy, 2001, 24, 459-471.	2.4	53
56	Correlation between the overexpression of Yin Yang 1 and the expression levels of miRNAs in Burkitt's lymphoma: A computational study. Oncology Letters, 2016, 11, 1021-1025.	1.8	53
57	RKIP: A Key Regulator in Tumor Metastasis Initiation and Resistance to Apoptosis: Therapeutic Targeting and Impact. Cancers, 2018, 10, 287.	3.7	53
58	Raf Kinase Inhibitor Protein (RKIP) Blocks Signal Transducer and Activator of Transcription 3 (STAT3) Activation in Breast and Prostate Cancer. PLoS ONE, 2014, 9, e92478.	2.5	53
59	Mechanism of Norepinephrine-Mediated Inhibition of Human NK Cytotoxic Functions: Inhibition of Cytokine Secretion, Target Binding, and Programming for Cytotoxicity. Brain, Behavior, and Immunity, 2002, 16, 227-246.	4.1	52
60	A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: Two complementary signals to overcome cross-resistance. Advances in Cancer Research, 2002, 85, 145-174.	5.0	50
61	YY1 Over-Expression in Human Brain Gliomas and Meningiomas Correlates with TGF-Î²1, IGF-1 and FGF-2 mRNA Levels. Cancer Investigation, 2009, 27, 184-192.	1.3	50
62	In vitro and in vivo sensitization of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: Involvement of AIF. Nitric Oxide - Biology and Chemistry, 2009, 20, 182-194.	2.7	49
63	Role of natural killer cytotoxic factors in the mechanism of target-cell killing by natural killer cells. Journal of Clinical Immunology, 1986, 6, 1-8.	3.8	46
64	Differential secretion of TNF-? and IFN-? by human peripheral blood-derived NK subsets and association with functional maturation. Journal of Clinical Immunology, 1996, 16, 46-54.	3.8	46
65	BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinoma. Cell Cycle, 2009, 8, 1402-1408.	2.6	46
66	Prognostic significance of YY1 protein expression and mRNA levels by bioinformatics analysis in human cancers: A therapeutic target. , 2015, 150, 149-168.		46
67	Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis. Cell Cycle, 2011, 10, 2792-2805.	2.6	45
68	Immunomodulatory effect of tumor necrosis factor. Biotherapy (Dordrecht, Netherlands), 1991, 3, 127-133.	0.7	44
69	Postulated Mechanisms of Resistance of B-Cell Non-Hodgkin Lymphoma to Rituximab Treatment Regimens: Strategies to Overcome Resistance. Seminars in Oncology, 2014, 41, 667-677.	2.2	43
70	Rituximab-Mediated Sensitization of B-Non-Hodgkin's Lymphoma (NHL) to Cytotoxicity Induced by Paclitaxel, Gemcitabine, and Vinorelbine. Cancer Biotherapy and Radiopharmaceuticals, 2002, 17, 621-630.	1.0	41
71	Nitric Oxide-Mediated Enhancement and Reversal of Resistance of Anticancer Therapies. Antioxidants, 2019, 8, 407.	5.1	40
72	2-Methoxyestradiol (2-ME) reduces the airway inflammation and remodeling in an experimental mouse model. Clinical Immunology, 2008, 129, 313-324.	3.2	39

#	Article	IF	Citations
73	Expression of phosphorylated raf kinase inhibitor protein (pRKIP) is a predictor of lung cancer survival. BMC Cancer, 2011, 11, 259.	2.6	39
74	Inverse correlation between the metastasis suppressor RKIP and the metastasis inducer YY1: Contrasting roles in the regulation of chemo/immuno-resistance in cancer. Drug Resistance Updates, 2017, 30, 28-38.	14.4	39
75	Overcoming cis-diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum (II) and tumor necrosis factorâ€“alpha. Cancer, 1993, 72, 809-818.	4.1	36
76	Repeated sub-optimal photodynamic treatments with pheophorbide a induce an epithelial mesenchymal transition in prostate cancer cells via nitric oxide. Nitric Oxide - Biology and Chemistry, 2015, 45, 43-53.	2.7	36
77	Targeting the Overexpressed YY1 in Cancer Inhibits EMT and Metastasis. Critical Reviews in Oncogenesis, 2017, 22, 49-61.	0.4	36
78	Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor-Î± and cis-diamminedichloroplatinum. Cancer, 1996, 77, 725-732.	4.1	33
79	Activation of Natural Killer Cells by Probiotics. Forum on Immunopathological Diseases and Therapeutics, 2016, 7, 41-55.	0.1	32
80	A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells. Leukemia and Lymphoma, 2011, 52, 108-121.	1.3	31
81	RKIP-Mediated Chemo-Immunosensitization of Resistant Cancer Cells via Disruption of the NF-ÎºB/Snail/YY1/RKIP Resistance-Driver Loop. Critical Reviews in Oncogenesis, 2014, 19, 431-445.	0.4	31
82	Sensitizing activities of nitric oxide donors for cancer resistance to anticancer therapeutic drugs. Biochemical Pharmacology, 2020, 176, 113913.	4.4	29
83	Viral Infection and Cancer: The NF-ÎºB/Snail/RKIP Loop Regulates Target Cell Sensitivity to Apoptosis by Cytotoxic Lymphocytes. Critical Reviews in Immunology, 2010, 30, 31-46.	0.5	29
84	Role of YY1 in the pathogenesis of prostate cancer and correlation with bioinformatic data sets of gene expression. Genes and Cancer, 2014, 5, 71-83.	1.9	29
85	Cycloheximide-induced modulation of TNF-mediated cytotoxicity in sensitive and resistant ovarian tumor cells. Cancer Chemotherapy and Pharmacology, 1990, 26, 1-8.	2.3	28
86	Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent. Drug Resistance Updates, 2007, 10, 1-12.	14.4	28
87	P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma. BMC Cancer, 2015, 15, 722.	2.6	28
88	Crosstalks between Raf-kinase inhibitor protein and cancer stem cell transcription factors (Oct4,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.8	28
89	Overexpression of Yin Yang 1 in bone marrow-derived human multiple myeloma and its clinical significance. International Journal of Oncology, 2014, 45, 1184-1192.	3.3	26
90	Platelet-activating factor and the cytokine network in inflammatory processes. Clinical Reviews in Allergy, 1995, 12, 381-395.	1.0	26

#	Article	IF	Citations
91	The NF-Î²B inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. Leukemia and Lymphoma, 2008, 49, 1982-1994.	1.3	25
92	The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-Î²B/Snail/RKIP/PTEN resistance loop in B-NHL cells: Role in sensitization to TRAIL apoptosis. International Journal of Oncology, 2011, 38, 1683-94.	3.3	25
93	Regulation of T Cells in Cancer by Nitric Oxide. Cells, 2021, 10, 2655.	4.1	25
94	Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: Independence of de novo protein synthesis. , 1999, 41, 20-30.		24
95	Overexpression of RKIP and its cross-talk with several regulatory gene products in multiple myeloma. Journal of Experimental and Clinical Cancer Research, 2017, 36, 62.	8.6	24
96	Inhibition of Epithelial-to-Mesenchymal Transition (EMT) in Cancer by Nitric Oxide: Pivotal Roles of Nitrosylation of NF-Î²B, YY1 and Snail. Forum on Immunopathological Diseases and Therapeutics, 2012, 3, 125-133.	0.1	24
97	Overcoming TNF-Î±and Drug Resistance of Human Renal Cell Carcinoma Cells by Treatment with Pentoxifylline in Combination with TNF-Î±or Drugs: The Role of TNF-Î±mRNA Downregulation in Tumor Cell Sensitization. Journal of Urology, 1994, 151, 1697-1702.	0.4	23
98	The NO TRAIL to YES TRAIL in cancer therapy (review). International Journal of Oncology, 2007, 31, 685-91.	3.3	23
99	Molecular Interactions in T-Cell-Mediated Cytotoxicity. Immunological Reviews, 1983, 72, 119-141.	6.0	22
100	Therapeutic YY1 Inhibitors in Cancer: ALL in ONE. Critical Reviews in Oncogenesis, 2017, 22, 37-47.	0.4	22
101	Linking Autophagy and the Dysregulated NFÎ²B/ SNAIL/YY1/RKIP/PTEN Loop in Cancer: Therapeutic Implications. Critical Reviews in Oncogenesis, 2018, 23, 307-320.	0.4	22
102	Transplantation of allogeneic lymphoid cells specifically depleted of graft versus host reactive cells. Nature, 1974, 249, 658-659.	27.8	20
103	Galiximab Signals B-NHL Cells and Inhibits the Activities of NF-Î²Bâ€“Induced YY1- and Snail-Resistant Factors: Mechanism of Sensitization to Apoptosis by Chemoimmunotherapeutic Drugs. Molecular Cancer Therapeutics, 2012, 11, 572-581.	4.1	20
104	Mechanism of activation of human peripheral blood NK cells at the single cell level by Echinacea water soluble extracts: recruitment of lymphocyteâ€“target conjugates and killer cells and activation of programming for lysis. International Immunopharmacology, 2003, 3, 811-824.	3.8	19
105	Overexpression of Yin Yang 1 in the Pathogenesis of Human Hematopoietic Malignancies. Critical Reviews in Oncogenesis, 2011, 16, 261-267.	0.4	18
106	Cytotoxic and cytostatic effects of the streptococcal preparation OK-432 and its subcellular fractions on human ovarian tumor cells. Cancer, 1989, 64, 434-441.	4.1	17
107	Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-Î± fusion protein: Direct cytotoxicity and synergy with chemotherapy. International Journal of Oncology, 2015, 47, 1735-1748.	3.3	16
108	Roles Each of Snail, Yin Yang 1, and RKIP in the Regulation of Tumor Cells Chemo- Immuno-Resistance to Apoptosis. Forum on Immunopathological Diseases and Therapeutics, 2013, 4, 79-92.	0.1	16

#	Article	IF	Citations
109	Direct estimation of frequency of cytotoxic T lymphocytes by a modified plaque assay. Nature, 1976, 263, 769-771.	27.8	15
110	Dysregulation of the cell survival/anti-apoptotic NF-ÎºB pathway by the novel humanized BM-ca anti-CD20 mAb: Implication in chemosensitization. International Journal of Oncology, 2009, 35, 1289-96.	3.3	15
111	A New Linkage between the Tumor Suppressor RKIP and Autophagy: Targeted Therapeutics. Critical Reviews in Oncogenesis, 2018, 23, 281-305.	0.4	15
112	Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma. Forum on Immunopathological Diseases and Therapeutics, 2011, 2, 179-188.	0.1	14
113	Death receptor 5 expression is inversely correlated with prostate cancer progression. Molecular Medicine Reports, 2014, 10, 2279-2286.	2.4	13
114	Autoantibodies Directed Against Moesin C471-577/N1-297 Are Novel and Specific Biomarkers of Immune Thrombocytopenic Purpura (ITP),. Blood, 2011, 118, 3301-3301.	1.4	13
115	The NO TRAIL to YES TRAIL in cancer therapy (Review). International Journal of Oncology, 2007, 31, 685.	3.3	11
116	Lysis of uninfected HIV-1 gp120-coated peripheral blood-derived T lymphocytes by monocyte-mediated antibody-dependent cellular cytotoxicity. FEMS Immunology and Medical Microbiology, 1995, 10, 83-92.	2.7	10
117	Sensitization of Rituximab-Resistant Ramos RR1 and Daudi RR1 Clones to Various Chemotherapeutic Drugs by a Novel Nuclear Factor-ÎºB Activation Inhibitor.. Blood, 2004, 104, 83-83.	1.4	10
118	Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's Lymphoma. Drug Resistance Updates, 2005, 8, 27-41.	14.4	9
119	Nitric Oxide Donors Are a New Class of Anti-cancer Therapeutics for the Reversal of Resistance and Inhibition of Metastasis. , 2010, , 459-477.		9
120	Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine. International Journal of Oncology, 2013, 43, 670-676.	3.3	9
121	Cellular and Molecular Characterization of Rituximab-Resistant CD20+ NHL Ramos (Ramos RR1) and Daudi (Daudi RR1) Clones: Development of Cross-Resistance to Cytotoxic Stimuli.. Blood, 2004, 104, 3410-3410.	1.4	9
122	Cell-mediated immune resistance in cancer. , 2020, 3, 232-251.		9
123	What signals are generated by anti-CD20 antibody therapy?. Current Hematologic Malignancy Reports, 2006, 1, 205-213.	2.3	8
124	Regulation Of Cell Death Apoptotic Pathways By Nitric Oxide In Cancer: Reversal Of Drug/Immune Resistance. Redox Biology, 2015, 5, 415.	9.0	8
125	YY1 Silencing Induces 5-Fluorouracil-Resistance and BCL2L15 Downregulation in Colorectal Cancer Cells: Diagnostic and Prognostic Relevance. International Journal of Molecular Sciences, 2021, 22, 8481.	4.1	8
126	Involvement of Yin Yang 1 (YY1) Expression in T-Cell Subsets Differentiation and Their Functions: Implications in T Cell-Mediated Diseases. Critical Reviews in Immunology, 2019, 39, 491-510.	0.5	8

#	Article	IF	Citations
127	The Forgotten YY2 in Reported YY1 Expression Levels in Human Cancers. Critical Reviews in Oncogenesis, 2017, 22, 63-73.	0.4	8
128	Role of the Transcription Factor Yin Yang 1 and Its Selectively Identified Target Survivin in High-Grade B-Cells Non-Hodgkin Lymphomas: Potential Diagnostic and Therapeutic Targets. International Journal of Molecular Sciences, 2020, 21, 6446.	4.1	7
129	Anti-Myeloma Activity by the Combination of the JAK2 Inhibitor Ruxolitinib with Lenalidomide and Corticosteroids. Blood, 2014, 124, 2114-2114.	1.4	7
130	Increased M2 Macrophages in Multiple Myeloma Patients with Progressive Disease and Down-Regulated Polarization with the JAK2 Inhibitor Ruxolitinib. Blood, 2014, 124, 4106-4106.	1.4	7
131	NK Cell Phenotypic and Functional Heterogeneities and Molecular Mechanisms of Cytotoxicity. Critical Reviews in Oncogenesis, 2014, 19, 21-45.	0.4	6
132	Prognostic Significance of Both the Cytoplasmic and Nuclear Overexpression of Yin-Yang 1 (YY1) among Patients with Multiple Myeloma (MM). Blood, 2008, 112, 2730-2730.	1.4	6
133	Cytotoxic Activity of Anti-CD20-hIFN-Î± on Rituximab-Resistant B-NHL Clones and Synergy with Chemotherapy,. Blood, 2011, 118, 3499-3499.	1.4	6
134	Pleitrophin Is Highly Expressed by Myeloma Cells, Elevated in the Serum of Myeloma Patients, and Is a New Autocrine Growth Factor for This B Cell Malignancy.. Blood, 2004, 104, 3349-3349.	1.4	6
135	Computational Analyses of YY1 and Its Target RKIP Reveal Their Diagnostic and Prognostic Roles in Lung Cancer. Cancers, 2022, 14, 922.	3.7	5
136	RKIP Pleiotropic Activities in Cancer and Inflammatory Diseases: Role in Immunity. Cancers, 2021, 13, 6247.	3.7	5
137	Special collection: Nitric oxide in cancer. Redox Biology, 2015, 6, 505-506.	9.0	4
138	Inhibition of Multiple Myeloma Cell Proliferation and Increase of Apoptosis through Regulation of the NF-ÎºB and JNK Pathways by Silencing TRAF6 C-Domain mRNA.. Blood, 2004, 104, 3355-3355.	1.4	4
139	Development of Rituximab-Resistant B-NHL Clones: An In Vitro Model for Studying Tumor Resistance to Monoclonal Antibody-Mediated Immunotherapy. Methods in Molecular Biology, 2011, 731, 407-419.	0.9	3
140	RKIP: A Pivotal Gene Product in the Pathogenesis of Cancer. Cancers, 2021, 13, 2488.	3.7	3
141	Ascorbic Acid Overcomes Drug Resistance in Myeloma and Significantly Increases the Anti-Myeloma Effects of both Arsenic Trioxide and Melphalan in Vitro and in Vivo.. Blood, 2004, 104, 2470-2470.	1.4	3
142	DETANONOate Is a Potent Chemo Radio-Sensitizing Agent in Colon and Colorectal Cancers as Assessed in In Vitro and In Vivo Established Tumor Xenografts. Forum on Immunopathological Diseases and Therapeutics, 2010, 1, 281-295.	0.1	3
143	Arsenic Trioxide Shows Synergistic Anti-Myeloma Effects When Combined with Bortezomib and Melphalan In Vitro and Helps Overcome Resistance of Multiple Myeloma Cells to These Treatments in Vivo.. Blood, 2004, 104, 2467-2467.	1.4	3
144	A spontaneous sarcoma dependent on host tumor-specific immune lymphocytes. BioEssays, 1989, 11, 181-185.	2.5	2

#	Article	IF	Citations
145	Novel Therapeutic Applications of Nitric Oxide in the Inhibition of Tumor Malignancy and Reversal of Resistance. , 2010, , 813-830.		2
146	Nitric Oxide Donors Sensitize Resistant Cancer Cells to Apoptosis Induced by Chemotherapy: Molecular Mechanisms of Sensitization. , 2017, , 15-34.		2
147	Defective Natural Killer Cells in Melanoma: Role of NKG2D in Pathogenesis and Immunotherapy. Critical Reviews in Immunology, 2021, 41, 45-76.	0.5	2
148	Abstract 5450: High expression of KrÃ¼ppel-Like Factor 4 (KLF4) and its regulation by Yin Yang 1 (YY1) in non-Hodgkin's B-cell lymphomas: clinical implication.. , 2013, , .		2
149	Sensitization of Rituximab-Sensitive and Rituximab-Resistant B-NHL Cell Lines/Clones to TRAIL-Induced Apoptosis by Bortezomib and NF-Î°B Inhibitors.. Blood, 2005, 106, 1514-1514.	1.4	2
150	Rituximab-Mediated Inhibition of the Transcription Repressor Yin-Yang 1 (YY1) in NHL B Cell Lines: Upregulation of Fas Expression and Sensitization to Fas-Induced Apoptosis.. Blood, 2004, 104, 287-287.	1.4	2
151	Cross Talk between the Circadian Clock Proteins and TP53 in Cancer and Therapeutic Significance. Critical Reviews in Oncogenesis, 2021, 26, 19-36.	0.4	2
152	Regulation of NKG2D by RKIP: Implications on NK-mediated cytotoxicity and cytokine production. , 2021, , 233-265.		1
153	YY1 expression and PD-1 regulation in CD8 T lymphocytes. , 2021, , 289-309.		1
154	YY1 is involved in the pathogenesis and malignant properties of human triple-negative breast cancer (TNBC). , 2021, , 149-162.		1
155	Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. , 1994, 74, 2546.		1
156	Lysis of uninfected HIV-1 gp120-coated peripheral blood-derived T lymphocytes by monocyte-mediated antibody-dependent cellular cytotoxicity. FEMS Immunology and Medical Microbiology, 1995, 10, 83-91.	2.7	1
157	Dual Roles of Raf-1 Kinase Inhibitor Protein in the Regulation of Both Tumor Cell Resistance to Apoptotic Stimuli and Epithelial to Mesenchymal Transition. Forum on Immunopathological Diseases and Therapeutics, 2011, 2, 95-109.	0.1	1
158	Blocking Pleiotrophin Activity Inhibits Multiple Myeloma (MM) Cell Growth In Vitro and in a Severe Combined Immunodeficient (SCID)-hu Murine Model of Human MM.. Blood, 2005, 106, 114-114.	1.4	1
159	Reversal of Rituximab-Resistant AIDS-B-NHL Clone to Chemotherapeutic Drug-Induced Apoptosis by Bortezomib and DHMEQ.. Blood, 2005, 106, 1516-1516.	1.4	1
160	Nitric Oxide Sensitizes B-NHL Cells to TRAIL-Mediated Apoptosis through Induction of RKIP, Inhibition of YY1 and Upregulation of DR5.. Blood, 2006, 108, 4604-4604.	1.4	1
161	Rituximab Sensitizes TRAIL-Resistant B-NHL Lines to Apoptosis by Both TRAIL and Fully Humanized Antibodies Targeting TRAIL-R1 (Mapatumumab) and TRAIL-R2 (Lexatumumab).. Blood, 2007, 110, 2350-2350.	1.4	1
162	Nitric Oxideâ€"Induced Immunosensitization to Apoptosis by Fas-L and TRAIL. , 2008, , 203-210.		1

#	Article	IF	Citations
163	Chemo-Immunosensitization of Resistant B-NHL as a Result of Rituximab (anti-CD20 mAb)-Mediated Inhibition of Cell Survival Signaling Pathways. , 2008, , 29-39.		1
164	KLF4 and YY1 Are Resistant Factors in NHL and Potential Therapeutic Targets: The New Resistant NF-Îºb/YY1/KLF4/BclxL/Mcl-1 Axis. Blood, 2015, 126, 1466-1466.	1.4	1
165	Pleiotropic activities of RKIP in cancer: Role in survival, EMT, chemo-immuno-resistance, and autophagy. , 2020, , 47-75.		1
166	Reversal of Resistance to Anti-CD20 Antibody Therapies: Targeting Intracellular Resistant Factors. Critical Reviews in Oncogenesis, 2020, 25, 275-290.	0.4	1
167	Identification of regulatory crosstalks between RKIP and BRCA1 tumor suppressors in healthy tissues and cancer (breast and ovarian): Therapeutic implications. , 2020, , 175-209.		1
168	Regulation of the c-myc Oncogene by the Circadian Clock and Oncogenesis. Critical Reviews in Oncogenesis, 2021, 26, 55-66.	0.4	1
169	Natural Killer Cells in HIV Infection and Role in the Pathogenesis of AIDS. , 0, , 183-205.		0
170	Preface: Special Issue on Yin Yang 1 and Oncogenesis. Critical Reviews in Oncogenesis, 2011, 16, 141-142.	0.4	0
171	Pivotal Role of Nitric Oxide in Chemo and Immuno Sensitization of Resistant Tumor Cells to Apoptosis. , 2015, , 179-201.		0
172	The role of YY1 in the pathogenesis of rheumatoid arthritis: A tale of cytokines, ncRNAs, and aberrant fibroblast-like synoviocytes (FLSs). , 2021, , 311-335.		0
173	The role of YY1 in drug resistant cancer: Involvement of the YY1/PTEN/PP2A/H2Ax/Rad51 axis. , 2021, , 225-242.		0
174	Pleitrophin Alone Induces Transdifferentiation of Human Monocytes and Bone Marrow Stem Cells into Endothelial Cells.. Blood, 2004, 104, 1472-1472.	1.4	0
175	Chemosensitization of Drug-Resistant Ramos B-NHL to Drug-Induced Apoptosis: YY1 Expression Is Decreased in Response to Cytoskeletal-Interacting Drugs.. Blood, 2005, 106, 4806-4806.	1.4	0
176	Circulating Tie2-Expressing Cells Are Increased in Multiple Myeloma Patients, Correlate with Serum Pleiotrophin Levels and May Develop from This Myeloma Angiogenic and Growth Factor.. Blood, 2005, 106, 2494-2494.	1.4	0
177	Analysis of YY1 and XIAP Expression, Proteins That Regulate Resistance, in AIDS-NHL Tissue Arrays.. Blood, 2005, 106, 1933-1933.	1.4	0
178	Overexpression and Preferential Nuclear Translocation of the Transcription Factor Yin Yang 1 (YY1) in Human Bone Marrow-Derived Multiple Myeloma.. Blood, 2005, 106, 3394-3394.	1.4	0
179	Serum Pleiotrophin Is a New Multiple Myeloma Tumor Marker That Also Predicts Clinical Status.. Blood, 2005, 106, 3417-3417.	1.4	0
180	Differential Presence of Truncated Forms of Transcription Factor Yin Yang 1 (YY1) in Bone Marrow of Multiple Myeloma Patients.. Blood, 2005, 106, 5083-5083.	1.4	0

#	Article	IF	Citations
181	Cytotoxicity of Genetically Engineered Fusion Protein with CD154 Peptide Mimetic (OmpC-CD154p) on B-NHL Cell Lines.. Blood, 2007, 110, 4525-4525.	1.4	0
182	Tumor Cell Resistance to Apoptosis by Infi ltrating Cytotoxic Lymphocytes. , 2008, , 121-137.		0
183	Nitric Oxide Inhibits Tumor Cell Metastasis via Dysregulation of the NF-Î°B/Snail/RKIP Loop. , 2010, , 209-233.		0
184	Reversal of Drug/TRAIL-Resistant B-NHL Cells to Apoptosis by the Combination of Rituximab (anti-CD20) and Either Mapatumumab or Lexatumumab. Blood, 2010, 116, 4931-4931.	1.4	0
185	Photodynamic Therapy (PDT)-Mediated Inhibition of the Transcription Factor Yin Yang 1 (YY1) That Regulates Resistance In Lymphoma. Blood, 2010, 116, 5113-5113.	1.4	0
186	Targeting the Over-Expressed Transcription Factor Yin-Yang 1 (YY1) Sensitizes Resistant Multiple Myeloma (MM) Cell Lines to Apoptosis by Bortezomib or Melphalan,. Blood, 2011, 118, 3991-3991.	1.4	0
187	Unresponsiveness to CHOP Is Associated with Activation of the p38 MAPK Pathway in Patients with DLBCL. Blood, 2011, 118, 2647-2647.	1.4	0
188	Upregulation of KLF4 Expression in Pediatric B-NHL Lymphomas and Its Association with Low EFS and Poor Survival Following Treatment with Chemotherapy. Blood, 2011, 118, 5184-5184.	1.4	0
189	Tumor Resistance to Antibody-Mediated Immunotherapy and Reversal of Resistance: Rituximab as Prototype. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 93-124.	0.1	0
190	Sensitization of Immune-Resistant Tumor Cells to CTL-Mediated Apoptosis via Interference at the Dysregulated NF-Î°B/Snail/YY1/PI3K/RKIP/PTEN Resistant Loop. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 177-208.	0.1	0
191	Yin Yang 1 (YY1) Acting Primarily As an Oncogene and Rarely As a Tumor Suppressor in Distinct Hematological Malignancies: Prognostic and Therapeutic Implications. Blood, 2016, 128, 5122-5122.	1.4	0
192	Identifying Crosstalk between Raf Kinase Inhibitor Protein and Systemic Lupus Erythematosus. Critical Reviews in Immunology, 2019, 39, 423-437.	0.5	0
193	Overexpression of YY1 Regulates the Resistance of Cancer Stem Cells: Targeting YY1. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 93-113.	0.1	0
194	Cross-Talk Cell Signaling between Anti-CD20 Antibodies and Nitric Oxide Donors. Critical Reviews in Oncogenesis, 2020, 25, 291-300.	0.4	0
195	Vivid Memories of Sercarz's Traineeship and Am Indebted to Him for My Professional Career. Critical Reviews in Immunology, 2020, 40, 347-352.	0.5	0
196	Crosstalks between Yin-Yang 1 (YY1) and autophagy in cancer. , 2020, , 9-27.		0
197	Commentary: Photodynamic Therapy-Induced Oxidative Stress and the Circadian Rhythm. Critical Reviews in Oncogenesis, 2021, 26, 67-73.	0.4	0